Correlation analysis of nuclear morphology, cytokeratin and Ki-67 expression of urothelial carcinoma cells

2013 ◽  
Vol 63 (6) ◽  
pp. 311-317 ◽  
Author(s):  
Masayo Shuto ◽  
Kenji Warigaya ◽  
Hiroshi Watanabe ◽  
Michio Shimizu ◽  
Toshio Fukuda ◽  
...  
Keyword(s):  
Correlation Analysis ◽  
Urothelial Carcinoma ◽  
Carcinoma Cells ◽  
Nuclear Morphology ◽  
Ki 67

scholarly journals Nested variant of urothelial carcinoma of the urinary bladder

Rare Tumors ◽  
2011 ◽  
Vol 3 (4) ◽  
pp. 132-134 ◽  
Author(s):  
Tadashi Terada
Keyword(s):  
Urothelial Carcinoma ◽  
Lamina Propria ◽  
Bladder Tumor ◽  
Clinical Course ◽  
Carcinoma Cells ◽  
Ki 67 ◽  
Atypical Cells ◽  
Nested Variant ◽  
Aggressive Clinical Course ◽  
Nephrogenic Metaplasia

The nested variant of urothelial carcinoma (NVUC) is characterized by the presence of benign-appearing urothelial carcinoma cells in the lamina propria, sparing the surface urothelial involvement. NVUC shows aggressive clinical course despite of benign-looking histology. Herein reported are two cases of NVUC. One is 80-year-old woman, and another is 78-year-old man. In both cases, atypical cells forming nests and tubules were seen in the lamina propria without surface urothelial involvement. One case resembled nephrogenic metaplasia and another proliferated Brunn's nest or inverted papilloma. Immunohistochemically, both cases showed positive p53 and high Ki67 labeling, suggesting that both cases are malignant. Immunohistochemically, one case was characterized by positive cytokeratins, EMA, p53, Ki-67 (labeling=15%), α-methylacyl CoA racemase, CA19-9, and MUC1, and another case by positive cytokeratins, EMA, p63, p53, Ki-67 (lebeling=30%), CD10, CEA, and MUC1. Cyto keratin immunoprofiles were described and other antigens’ expressions were shown. The patients are now free of tumor 6 and 15 months after the resection of the bladder tumor.

Genotyping of high-risk human papillomaviruses in p16/Ki-67-positive urothelial carcinoma cells: even a worm will turn

Cytopathology ◽  
2014 ◽  
Vol 26 (2) ◽  
pp. 106-113 ◽  
Author(s):  
A.-S. Advenier ◽  
J.-S. Casalegno ◽  
Y. Mekki ◽  
M. Decaussin-Petrucci ◽  
F. Mège-Lechevallier ◽  
...  
Keyword(s):  
High Risk ◽  
Urothelial Carcinoma ◽  
Human Papillomaviruses ◽  
Carcinoma Cells ◽  
Ki 67

Scattered sarcomatoid urothelial carcinoma cells within MALT lymphoma of the urinary bladder

2016 ◽  
Vol 10 (3) ◽  
pp. 267-270
Author(s):  
Tadashi Terada
Keyword(s):  
T Cells ◽  
B Cells ◽  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Surface Area ◽  
Malt Lymphoma ◽  
Carcinoma Cells ◽  
Low Grade ◽  
Ki 67 ◽  
Non Invasive

Recently the author encountered a peculiar tumour of the bladder consisting of the following three components: MALT lymphoma, scattered poorly cohesive sarcomatoid urothelial carcinoma within MALT lymphoma, and surface non-invasive, low-grade conventional urothelial carcinoma (UC) occurring in a 65-year-old female. A low-power view showed MALT. Meticulous observations revealed a small amount of non-invasive, low-grade conventional UC at the surface area. In addition, meticulous observations identified a small number of cytokeratin-positive, poorly cohesive sarcomatoid UC cells scattered within the MALT lymphoma. The MALT lymphoma was typical. Immunohistochemically, the scattered sarcomatoid cells within the MALT lymphoma were positive for various types of CK, EMA, p53 and Ki-67 (LI = 70%). The MALT lymphoma was composed mainly of B-cells (CD10, CD20, CD23, CD79α, κ-chains and λ-chain), but T-cells positive for CD3, CD4, CD5, CD43 or CD45RO were seen in a very small number. This scattering sarcomatoid UC within MALT lymphoma of bladder has not been reported.

Developing a nomogram for predicting intravesical recurrence after radical nephroureterectomy: a retrospective cohort study of mainland Chinese patients

2021 ◽  
Author(s):  
Shicong Lai ◽  
Xingbo Long ◽  
Pengjie Wu ◽  
Jianyong Liu ◽  
Samuel Seery ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Cox Regression ◽  
Upper Tract Urothelial Carcinoma ◽  
Chinese Patients ◽  
Clinicopathological Parameters ◽  
Radical Nephroureterectomy ◽  
Ki 67 ◽  
Data Set ◽  
Mainland Chinese ◽  
Upper Tract

Abstract Objective To evaluate the role of Ki-67 in predicting subsequent intravesical recurrence following radical nephroureterectomy and to develop a predictive nomogram for upper tract urothelial carcinoma patients. Methods This retrospective analysis involved 489 upper tract urothelial carcinoma patients who underwent radical nephroureterectomy with bladder cuff excision. The data set was randomly split into a training cohort of 293 patients and a validation cohort of 196 patients. Immunohistochemical analysis was used to assess the immunoreactivity of the biomarker Ki-67 in the tumor tissues. A multivariable Cox regression model was utilized to identify independent intravesical recurrence predictors after radical nephroureterectomy before constructing a nomographic model. Predictive accuracy was quantified using time-dependent receiver operating characteristic curve. Decision curve analysis was performed to evaluate the clinical benefit of models. Results With a median follow-up of 54 months, intravesical recurrence developed in 28.2% of this sample (n = 137). Tumor location, multifocality, pathological T stage, surgical approach, bladder cancer history and Ki-67 expression levels were independently associated with intravesical recurrence (all P < 0.05). The full model, which intercalated Ki-67 with traditional clinicopathological parameters, outperformed both the basic model and Xylinas’ model in terms of discriminative capacity (all P < 0.05). Decision-making analysis suggests that the more comprehensive model can also improve patients’ net benefit. Conclusions This new model, which intercalates the Ki-67 biomarker with traditional clinicopathological factors, appears to be more sensitive than nomograms previously tested across mainland Chinese populations. The findings suggest that Ki-67 could be useful for determining risk-stratified surveillance protocols following radical nephroureterectomy and in generating an individualized strategy based around intravesical recurrence predictions.

scholarly journals The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dexin Shen ◽  
Yayun Fang ◽  
Fenfang Zhou ◽  
Zhao Deng ◽  
Kaiyu Qian ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Urothelial Carcinoma ◽  
Carcinoma Cells ◽  
Expression Level ◽  
Tumor Cell Growth ◽  
Migration Ability ◽  
Bladder Urothelial Carcinoma ◽  
Related Proteins

Abstract Background CDCA3 is an important component of the E3 ligase complex with SKP1 and CUL1, which could regulate the progress of cell mitosis. CDCA3 has been widely identified as a proto-oncogene in multiple human cancers, however, its role in promoting human bladder urothelial carcinoma has not been fully elucidated. Methods Bioinformatic methods were used to analyze the expression level of CDCA3 in human bladder urothelial carcinoma tissues and the relationship between its expression level and key clinical characteristics. In vitro studies were performed to validate the specific functions of CDCA3 in regulating cell proliferation, cell migration and cell cycle process. Alterations of related proteins was investigated by western blot assays. In vivo studies were constructed to validate whether silencing CDCA3 could inhibit the proliferation rate in mice model. Results Bioinformatic analysis revealed that CDCA3 was significantly up-regulated in bladder urothelial carcinoma samples and was related to key clinical characteristics, such as tumor grade and metastasis. Moreover, patients who had higher expression level of CDCA3 tend to show a shorter life span. In vitro studies revealed that silencing CDCA3 could impair the migration ability of tumor cells via down-regulating EMT-related proteins such as MMP9 and Vimentin and inhibit tumor cell growth via arresting cells in the G1 cell cycle phase through regulating cell cycle related proteins like p21. In vivo study confirmed that silencing CDCA3 could inhibit the proliferation of bladder urothelial carcinoma cells. Conclusions CDCA3 is an important oncogene that could strengthen the migration ability of bladder urothelial carcinoma cells and accelerate tumor cell growth via regulating cell cycle progress and is a potential biomarker of bladder urothelial carcinoma.

scholarly journals Molecular Markers in Upper Urothelial Carcinoma Associated to Balkan Endemic Nephropathy. Aristolochic Acid as the Major Risk Factor of the Worldwide Disease

2009 ◽  
Vol 9 ◽  
pp. 1360-1373 ◽  
Author(s):  
Ljubinka Jankovic Velickovic ◽  
Takanori Hattori ◽  
Vladisav Stefanovic
Keyword(s):  
Regression Analysis ◽  
Urothelial Carcinoma ◽  
Growth Stage ◽  
Aristolochic Acid ◽  
Balkan Endemic Nephropathy ◽  
Specific Cell ◽  
Ki 67 ◽  
High Stage ◽  
Endemic Nephropathy

The role of aristolochic acid in the etiology of Balkan endemic nephropathy (BEN) and associated upper urothelial carcinoma (UUC) was recently confirmed. The aim of this study was to determine the marker(s) specific for BEN-associated UUC. A total of 82 patients with UUC (38 from the BEN region and 44 control tumors) were included in the study. The Ki-67 index in BEN tumors correlated with the grade and multifocality (p< 0.05), but in regression analysis, only the grade of BEN tumor. The p53 index was significantly higher in BEN than in control tumors (p< 0.05), as well as the alteration of p53 (p< 0.05). BEN low-stage tumors, tumors without limphovascular invasion (LVI), and tumors of the renal pelvis had a higher p53 index than the control tumors (p< 0.05, 0.01, 0.05, respectively). The Ki-67 index was higher in control tumors with high-stage and solid growth than in BEN UUC (p < 0.050, 0.005). The Ki-67 correlated with the grade, growth, stage, LVI, and multifocality of UUC on the best way, but not with the group. In regression analysis, only multifocality of UUC had predictive influence on Ki-67 activity (p< 0.001). P53 correlated with the grade, growth, and group (p< 0.05). This investigation identifies the p53 pathway as the specific cell cycle marker involved in BEN-associated UUC.

scholarly journals Expression of HER2/neu and Ki-67 in Urothelial Carcinoma and their Relation to Clinicopathological Data: An Egyptian Study

2021 ◽  
Author(s):  
Badawia B Ibrahim ◽  
Samira A Mahmoud ◽  
Alzahraa A Mohamed ◽  
Hala M El Hanbuli
Keyword(s):  
Urothelial Carcinoma ◽  
Bladder Carcinoma ◽  
Histological Grade ◽  
P Value ◽  
Urinary Bladder Carcinoma ◽  
Ki 67 ◽  
Urothelial Bladder Carcinoma ◽  
Cellular Marker ◽  
Urothelial Bladder ◽  
Common Malignancy

Introduction: Bladder cancer is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide. Ki-67 is a nonhistone cellular marker for proliferation. HER2/neu is an oncogene that plays an important role in the pathogenesis of many cancer types. In bladder carcinoma, its clinical significance remains under-investigated and poorly linked to the patients’ clinicopathological features especially with no reported Egyptian study. Aim: The aim of this work was to study the expression of HER2/neu and Ki-67 in urinary bladder carcinoma to evaluate their role in tumourigenesis and their correlation with other available clinicopathological variables associated with urothelial carcinoma. Materials and Methods: This cross-sectional study was conducted at the Department of Pathology, Faculty of Medicine, Cairo University, Egypt. Samples were paraffin blocks from 60 cases diagnosed with urothelial carcinoma underwent radical cystectomy. Ki-67 and HER2/neu immunohistochemical staining was done and of Ki-67 and HER2/neu Immunostaining was recorded. The associations between Ki-67, HER2/neu expressions and clinical and histopathological parameters of urothelial bladder carcinoma was evaluated. Results: The Ki-67 expression had significant association with tumour histological grade and lymphovascular invasion (p-value <0.05). The association of HER2/neu expression had significant association with perineural invasion (p-value <0.05). Conclusion: HER2/neu immunostaining was not associated with most of the clinicopathologic prognostic factors in urothelial bladder carcinoma.

scholarly journals Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells

2020 ◽  
Vol 98 (4) ◽  
pp. 355-367 ◽  
Author(s):  
Alessandro Nini ◽  
Michèle Janine Hoffmann ◽  
Rita Lampignano ◽  
Robert große Siemer ◽  
Guus Dalum ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Carcinoma Cells ◽  
Her2 Expression

THE EFFECTS OF PHYSIOLOGIC ESTROGEN CONCENTRATIONS ON THE BCG-INDUCED IMMUNE RESPONSE IN HUMAN UROTHELIAL CARCINOMA CELLS

2009 ◽  
Vol 181 (4S) ◽  
pp. 411-411
Author(s):  
Fanghong Chen ◽  
Amy Guise ◽  
Guangjian Zhang ◽  
William A See
Keyword(s):  
Immune Response ◽  
Urothelial Carcinoma ◽  
Carcinoma Cells
Sign in / Sign up

Export Citation Format

Share Document